.png)
Bio-entrepreneurship plays a vital role in the COVID-19 pandemic, with companies developing products to prevent the further transmission of the virus. Due to the pandemic there have been increased collaborations between startup companies that harness deep technology in their innovations. Deep technology, or Deep Tech, offers the chance to solve big societal problems in healthcare, urban mobility and other issues. In the context of healthcare, Deep Tech has been used in artificial intelligence diagnosis and genome sequencing. One such example is the iThermo, an AI-powered temperature screener built by local healthcare AI startup KroniKare to identify those displaying symptoms of a fever.
​
Commercialisation of such scientific discoveries however, is a high-risk venture that requires both a lot of capital and patience. Investments thus play a crucial role in supporting the sustainability of an entrepreneurship business. In this track, we will discuss bio-entrepreneurship from the point of view of the investors, exploring how the COVID-19 pandemic affects investor focus in the biopharmaceutical industry.
S p e a k e r s
S p e a k e r s
S p e a k e r s
S p e a k e r s
Dr. Ma Siming received BA in Natural Sciences (Biological) from University of Cambridge in 2010 and PhD in Biological and Biomedical Sciences from Harvard University in 2016, under A*STAR NSS (BS/PhD) Scholarship. He has been seconded to ImmunoScape under the A*STAR T-Up Program to work on bioinformatics method development and data integration. He is currently Associate Director, Project Management, and helps coordinate the various projects across the company.
Dr Ma Si Ming
Dr. Natasha Ng received her BSc in Biology at Imperial College London and PhD in Medical Sciences at the University of Oxford in 2016. She is currently the President of Biotech Connection Singapore and Senior Research Fellow in IMCB, A*STAR working on stem cells and diabetes. She also gained experience in bio-entrepreneurship when she was the co-founder of BioMe Oxford, an early-stage medical device start up.
Dr Natasha Ng
Dr. Paul Gallagher received his PhD from The University of Dublin in 1994, under the Trinity College Dublin Trust Postgraduate Scholarship, and attained the EOLAS Postgraduate Research award. He is currently a professor (practice track) at NUS, Department of Pharmacy. His research interest is in the development and evaluation of interventions in the community pharmacy.
Dr Paul Gallagher
.png)
.png)
